Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.58 |
| ▸ | RAB9A | P51151 | 4/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | BACE1 | P56817 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.43 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.43 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.42 |
| ▸ | CTSG | P08311 | 1/20 | 0.42 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.42 |
| ▸ | CMA1 | P23946 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7689672 | 1.00 | NPC1 (0.58) | NPC1RAB9ASMN1; SMN2GAABACE1 | |
| SCHEMBL30483952 | 0.91 | NPC1 (0.51) | NPC1RAB9ASMN1; SMN2EPHX2LMNA | |
| Mannitol SCHEMBL29038510 | 0.84 | ALDH1A1 (0.47) | NPC1RAB9ASMN1; SMN2GAAEPHX2 | |
| SCHEMBL7148071 | 0.83 | NPC1 (0.54) | NPC1RAB9ASMN1; SMN2GAABACE1 | |
| SCHEMBL18992673 | 0.82 | THRB (0.61) | NPC1RAB9ASMN1; SMN2EPHX2KMT2A | |
| SCHEMBL30809838 | 0.82 | ATM (0.60) | NPC1RAB9ASMN1; SMN2GAAKMT2A | |
| SCHEMBL3465056 | 0.81 | NPC1 (0.64) | NPC1RAB9ASMN1; SMN2GAABACE1 | |
| SCHEMBL6154030 | 0.81 | NPC1 (0.64) | NPC1RAB9ASMN1; SMN2GAABACE1 | |
| SCHEMBL20234449 | 0.80 | SMN1; SMN2 (0.48) | NPC1RAB9ASMN1; SMN2GAABACE1 | |
| SCHEMBL19334001 | 0.79 | SMN1; SMN2 (0.62) | NPC1RAB9ASMN1; SMN2GAABACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9045523-B2 | Compounds | PHAROS PHARMACEUTICALS INC. (US) | 2015-06-02 | — | — | US | disclosed |
| EP-2586786-A1 | Sulphated amino sugars with anti-inflammatory properties | Diosamine Development Corporation (US) | 2013-05-01 | — | — | EP | disclosed |
| US-20110044901-A1 | NOVEL COMPOUNDS | DIOSAMINE DEVELOPMENT CORPORATION (US) | 2011-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110044901-A1 | NOVEL COMPOUNDS | AREG, CCL2, CRH | NPC1 4848/4885RAB9A 3073/4885SMN1; SMN2 3745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.